{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T09:47:39Z","timestamp":1768297659907,"version":"3.49.0"},"reference-count":154,"publisher":"Akademiai Kiado Zrt.","issue":"4","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Establishment of an expert system to support personalized medicine for managing the care of infectious and major public health diseases","award":["\u201eBefektet\u00e9s a j\u00f6v\u0151be Alap\u201d 2020-1.1.6-J\u00d6V\u0150-2021-00011"],"award-info":[{"award-number":["\u201eBefektet\u00e9s a j\u00f6v\u0151be Alap\u201d 2020-1.1.6-J\u00d6V\u0150-2021-00011"]}]}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["AMicr"],"published-print":{"date-parts":[[2021,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n            <jats:p>Allogeneic hematopoietic stem cell transplantation (HSCT) and coronavirus disease 2019 (COVID-19) infection can both lead to severe cytokine release syndrome (sCRS) resulting in critical illness and death. In this single institution, preliminary comparative case-series study we compared clinical and laboratory co-variates as well as response to tocilizumab (TCZ)-based therapy of 15 allogeneic-HSCT- and 17 COVID-19-associated sCRS patients. Reaction to a TCZ plus posttransplant cyclophosphamide (PTCY) consolidation therapy in the allogeneic-HSCT-associated sCRS group yielded significantly inferior long-term outcome as compared to TCZ-based therapy in the COVID-19-associated group (<jats:italic>P<\/jats:italic> = 0.003). We report that a TCZ followed by consolidation therapy with a Janus kinase\/signal transducer and activator of transcription (JAK\/STAT) inhibitor given to 4 out of 8 critically ill COVID-19 patients resulted in their complete recovery. Non-selective JAK\/STAT inhibitors influencing the action of several cytokines exhibit a broader effect than TCZ alone in calming down sCRS. Serum levels of cytokines and chemokines show similar changes in allogeneic-HSCT- and COVID-19-associated sCRS with marked elevation of interleukin-6 (IL-6), regulated upon activation normal T-cell expressed and secreted (RANTES), monocyte chemoattractant protein-1 (MCP-1) and interferon <jats:italic>\u03b3<\/jats:italic>-induced protein 10\u2009kDa (IP-10) levels. In addition, levels of IL-5, IL-10, IL-15 were also elevated in allogeneic-HSCT-associated sCRS. Our multi-cytokine expression data indicate that the pathophysiology of allogeneic-HSCT and COVID-19-associated sCRS are similar therefore the same clinical grading system and TCZ-based treatment approaches can be applied. TCZ with JAK\/STAT inhibitor consolidation therapy might be highly effective in COVID-19 sCRS patients.<\/jats:p>","DOI":"10.1556\/030.2021.01620","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T14:43:31Z","timestamp":1637333011000},"page":"240-255","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":3,"title":["Common points of therapeutic intervention in COVID-19 and in allogeneic hematopoietic stem cell transplantation associated severe cytokine release syndrome"],"prefix":"10.1556","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-7049","authenticated-orcid":true,"given":"L\u00e1szl\u00f3","family":"Gopcsa","sequence":"first","affiliation":[{"name":"Central Hospital of Southern-Pest, National Institute of Hematology and Infectious Diseases, Department of Hematology and Stem Cell Transplantation, Albert Florian ut 5-7, H-1097, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilona","family":"Bobek","sequence":"additional","affiliation":[{"name":"Central Hospital of Southern-Pest, National Institute of Hematology and Infectious Diseases, Department of Intensive Care Unit, Albert Florian ut 5-7, H-1097, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Bek\u0151","sequence":"additional","affiliation":[{"name":"Central Hospital of Southern-Pest, National Institute of Hematology and Infectious Diseases, Department of Central Laboratory, Albert Florian ut 5-7, H-1097, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Botond","family":"Lakatos","sequence":"additional","affiliation":[{"name":"Central Hospital of Southern-Pest, National Institute of Hematology and Infectious Diseases, Department of Infectious Diseases, Albert Florian ut 5-7, H-1097, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eszter","family":"Moln\u00e1r","sequence":"additional","affiliation":[{"name":"Central Hospital of Southern-Pest, National Institute of Hematology and Infectious Diseases, Department of Intensive Care Unit, Albert Florian ut 5-7, H-1097, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marienn","family":"R\u00e9ti","sequence":"additional","affiliation":[{"name":"Central Hospital of Southern-Pest, National Institute of Hematology and Infectious Diseases, Department of Hematology and Stem Cell Transplantation, Albert Florian ut 5-7, H-1097, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Rem\u00e9nyi","sequence":"additional","affiliation":[{"name":"Central Hospital of Southern-Pest, National Institute of Hematology and Infectious Diseases, Department of Hematology and Stem Cell Transplantation, Albert Florian ut 5-7, H-1097, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e1nos","family":"Sink\u00f3","sequence":"additional","affiliation":[{"name":"Central Hospital of Southern-Pest, National Institute of Hematology and Infectious Diseases, Department of Hematology and Stem Cell Transplantation, Albert Florian ut 5-7, H-1097, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e1nos","family":"Szl\u00e1vik","sequence":"additional","affiliation":[{"name":"Central Hospital of Southern-Pest, National Institute of Hematology and Infectious Diseases, Department of Infectious Diseases, Albert Florian ut 5-7, H-1097, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e1bor","family":"Tatai","sequence":"additional","affiliation":[{"name":"Central Hospital of Southern-Pest, National Institute of Hematology and Infectious Diseases, Department of Hematology and Stem Cell Transplantation, Albert Florian ut 5-7, H-1097, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istv\u00e1n","family":"V\u00e1lyi-Nagy","sequence":"additional","affiliation":[{"name":"Central Hospital of Southern-Pest, National Institute of Hematology and Infectious Diseases, Department of Hematology and Stem Cell Transplantation, Albert Florian ut 5-7, H-1097, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref1181","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with COVID-19","volume":"384","author":"Gordon","year":"2021","journal-title":"N Engl J Med"},{"key":"ref1241","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1016\/S2665-9913(21)00012-6","article-title":"Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study","volume":"3","author":"Cavalli","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s40265-020-01367-z","article-title":"Pharmaco-immunomodulatory therapy in COVID-19","volume":"80","author":"Rizk","year":"2020","journal-title":"Drugs"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/sj.leu.2402946","article-title":"Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation","volume":"17","author":"Schots","year":"2003","journal-title":"Leukemia"},{"key":"ref1301","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/j.bbmt.2019.07.027","article-title":"Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation","volume":"25","author":"Imus","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"ref881","article-title":"https www fda gov news events press announcements coronavirus covid update fda authorizes drug treatment covid Accessed","volume":"19","author":"Jun","year":"2021"},{"key":"ref671","article-title":"https clinicaltrials gov ct show Accessed","volume":"15","year":"2021","journal-title":"Mar"},{"key":"ref1371","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10875-020-00911-6","article-title":"Tocilizumab for severe worsening COVID-19 pneumonia: a propensity score analysis","volume":"41","author":"Roumier","year":"2021","journal-title":"J Clin Immunol"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"ref1091","article-title":"Prognostic and predictive biomarkers in patients with COVID-19 treated with tocilizumab in a randomized controlled trial","author":"Tom","year":"2020","journal-title":"medRxiv"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1111\/bjh.16979","article-title":"Ruxolitinib for tocilizumab-refractory severe COVID-19 infection","volume":"190","author":"Innes","year":"2020","journal-title":"Br J Haematol"},{"key":"ref661","article-title":"https clinicaltrials gov ct show Accessed","author":"Jun","year":"2021"},{"key":"ref1151","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with Covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl J Med"},{"key":"ref1381","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00134-021-06416-z","article-title":"Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials","volume":"47","author":"Snow","year":"2021","journal-title":"Intensive Care Med"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijid.2020.07.081","article-title":"Early identification of COVID-19 cytokine strom and treatment with anakinra or tocilizumab","volume":"99","author":"Langer-Gould","year":"2020","journal-title":"Int J Infect Dis"},{"key":"ref1481","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe4724","article-title":"JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality","volume":"7","author":"Stebbing","year":"2021","journal-title":"Sci Adv"},{"key":"ref1341","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12879-021-05912-3","article-title":"Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India","volume":"21","author":"Gokhale","year":"2021","journal-title":"BMC Infect Dis"},{"key":"ref1361","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.jinf.2020.07.008","article-title":"Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: a comparative analysis","volume":"81","author":"Rossotti","year":"2020","journal-title":"J Infect"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/TCRM.S150524","article-title":"Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy","volume":"15","author":"Riegler","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41375-020-01087-z","article-title":"Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia","volume":"35","author":"D\u2019Alessio","year":"2021","journal-title":"Leukemia"},{"key":"ref1251","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1093\/cid\/ciaa954","article-title":"Tocilizumab for treatment of mechanically ventilated patients with COVID-19","volume":"73","author":"Somers","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia. A randomized clinical trial","volume":"181","author":"Hermine","year":"2020","journal-title":"JAMA Intern Med"},{"key":"ref981","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"ref131","article-title":"Experience with the use of baricitinib and tocilizumab monotherapy or combined, in patients with interstitial pneumonia secondary to coronavirus COVID19: a real-world study","author":"Rosas","year":"2020","journal-title":"Reumatol Clin"},{"key":"ref1321","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237831","article-title":"Tocilizumab and steroid treatment in patients with COVID-19 pneumonia","volume":"15","author":"Mikulska","year":"2020","journal-title":"PLos One"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"108393","DOI":"10.1016\/j.clim.2020.108393","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspective of clinical immunologists from China","volume":"214","author":"Zhang","year":"2020","journal-title":"Clin Immunol"},{"key":"ref581","first-page":"317","article-title":"Effect of tocilizumab in hospitalized patients with severe pneumonia COVID-19: a cohort study","volume":"13","author":"Rossi","year":"2020","journal-title":"medRxiv"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"ref761","article-title":"Disruption of the CCL5\/RANTES-CCR5 pathway restore immune homeostasis and reduces plasma viral load in critical COVID-19","author":"Patterson","year":"2020","journal-title":"medRxiv"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41409-020-01060-5","article-title":"Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy","volume":"56","author":"Hong","year":"2021","journal-title":"Bone Marrow Transpl"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia. A randomized clinical trial","volume":"181","author":"Hermine","year":"2020","journal-title":"JAMA Intern Med"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1016\/S2665-9913(21)00012-6","article-title":"Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study","volume":"3","author":"Cavalli","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"ref1421","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/s41375-020-01018-y","article-title":"Compassionate use of JAK1\/2 inhibitor ruxolitinib for severe COVID-19: a retrospective observational study","volume":"35","author":"Vannucchi","year":"2021","journal-title":"Leukemia"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"The Lancet"},{"key":"ref1041","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1093\/cid\/ciaa449","article-title":"Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients","volume":"71","author":"Chen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/intimm\/dxab011","article-title":"IL-6: from arthritis to CAR-T-cell therapy and COVID-19","volume":"33","author":"Kishimoto","year":"2021","journal-title":"Int Immunol"},{"key":"ref431","article-title":"https clinicaltrials gov ct show Accessed","volume":"11","year":"2021","journal-title":"Mar"},{"key":"ref1391","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial","volume":"146","author":"Cao","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"ref1231","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1186\/s12879-020-05701-4","article-title":"Effects of tocilizumab in COVID-19 patients: a cohort study","volume":"20","author":"Vu","year":"2020","journal-title":"BMC Infect Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/j.bbmt.2019.07.027","article-title":"Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation","volume":"25","author":"Imus","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1093\/cid\/ciaa954","article-title":"Tocilizumab for treatment of mechanically ventilated patients with COVID-19","volume":"73","author":"Somers","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijid.2020.07.081","article-title":"Early identification of COVID-19 cytokine strom and treatment with anakinra or tocilizumab","volume":"99","author":"Langer-Gould","year":"2020","journal-title":"Int J Infect Dis"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1556\/650.2020.31901","article-title":"Successful administration of convalescent plasma in critically ill COVID-19 patients in Hungary: the first two cases","volume":"161","author":"Bobek","year":"2020","journal-title":"Orvosi Hetilap"},{"key":"ref1211","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cmi.2020.10.036","article-title":"Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis","volume":"27","author":"Tleyjeh","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fimmu.2020.00026","article-title":"Novel insights into immune systems of bats","volume":"11","author":"Banerjee","year":"2020","journal-title":"Front Immunol"},{"key":"ref1461","first-page":"00331","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19 (COV-BARRIER): a randomized, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"S2213-2600","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/TCRM.S150524","article-title":"Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy","volume":"15","author":"Riegler","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"ref561","article-title":"Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection","author":"Moreno-Garc\u00eda","year":"2020","journal-title":"medRxiv"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"7546","DOI":"10.1200\/JCO.2020.38.15_suppl.7546","article-title":"Grade III-IV cytokine release syndrome is associated with inferior survival in patients undergoing haploidentical donor stem cell transplant","volume":"38","author":"Albanyan","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ajcp\/aqaa124","article-title":"SARS-CoV-2 infection-associated hemophagocytic lymphohistiocytosis","volume":"154","author":"Prilutskiy","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.jinf.2020.07.008","article-title":"Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: a comparative analysis","volume":"81","author":"Rossotti","year":"2020","journal-title":"J Infect"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"108393","DOI":"10.1016\/j.clim.2020.108393","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspective of clinical immunologists from China","volume":"214","author":"Zhang","year":"2020","journal-title":"Clin Immunol"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jamainternmed.2020.6252","article-title":"Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19","volume":"181","author":"Gupta","year":"2020","journal-title":"JAMA Intern Med"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial","volume":"181","author":"Salvarani","year":"2020","journal-title":"JAMA Intern Med"},{"key":"ref1501","article-title":"https www fdanews com articles fda changes eua so olumiant can stand alone in treating covid v preview Accessed Jul","volume":"19","year":"2021"},{"key":"ref1511","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.16966","article-title":"Combined IL-6 and JAK\/STAT inhibitor therapy in COVID-19-related sHLH, potential game changer","volume":"190","author":"Portsmore","year":"2020","journal-title":"Br J Haematol"},{"key":"ref1471","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/rheumatology\/keaa587","article-title":"Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study","volume":"60","author":"Rodriguez-Garcia","year":"2021","journal-title":"Rheumatology"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/sj.leu.2402946","article-title":"Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation","volume":"17","author":"Schots","year":"2003","journal-title":"Leukemia"},{"key":"ref1031","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40249-020-00662-x","article-title":"Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues","volume":"9","author":"Li","year":"2020","journal-title":"Infect Dis Poverty"},{"key":"ref991","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy-assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s40265-020-01367-z","article-title":"Pharmaco-immunomodulatory therapy in COVID-19","volume":"80","author":"Rizk","year":"2020","journal-title":"Drugs"},{"key":"ref941","first-page":"145","article-title":"Laboratory parameters predicting mortality of adult in-patients with COVID-19 associated cytokine release syndrome treated with high-dose tocilizumab","volume":"68","author":"Lakatos","year":"2021","journal-title":"Acta Microbiol Immunol Hung"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40249-020-00662-x","article-title":"Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues","volume":"9","author":"Li","year":"2020","journal-title":"Infect Dis Poverty"},{"key":"ref1011","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the \u2018Cytokine Storm\u2019 in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"J Infect"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/rheumatology\/keaa587","article-title":"Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study","volume":"60","author":"Rodriguez-Garcia","year":"2021","journal-title":"Rheumatology"},{"key":"ref711","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe4724","article-title":"JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality","volume":"7","author":"Stebbing","year":"2021","journal-title":"Sci Adv"},{"key":"ref1261","article-title":"Off-label real wold experience using tocilizumab for patients hospitalized with COVID-19 disease in a regional community healt system: a case-control study","author":"Ramaswamy","year":"2020","journal-title":"medRxiv"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","article-title":"Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated","volume":"22","author":"Abboud","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.tips.2020.06.007","article-title":"Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19","volume":"41","author":"Luo","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"ref1521","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1111\/bjh.16979","article-title":"Ruxolitinib for tocilizumab-refractory severe COVID-19 infection","volume":"190","author":"Innes","year":"2020","journal-title":"Br J Haematol"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"ref891","article-title":"https www ema europa eu en news ema starts evaluating use roactemra hospitalised adults severe covid Accessed Aug","volume":"19","year":"2021"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1016\/S2665-9913(20)30277-0","article-title":"Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study","volume":"2","author":"Biran","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1093\/cid\/ciaa449","article-title":"Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients","volume":"71","author":"Chen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref1451","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jinf.2020.06.052","article-title":"Beneficial impact of baricitinib in COVID-19 moderate pneumonia; multicentre study","volume":"81","author":"Cantini","year":"2020","journal-title":"J Infect"},{"key":"ref901","article-title":"Experience with the use of baricitinib and tocilizumab monotherapy or combined, in patients with interstitial pneumonia secondary to coronavirus COVID19: a real-world study","author":"Rosas","year":"2020","journal-title":"Reumatol Clin"},{"key":"ref1351","first-page":"317","article-title":"Effect of tocilizumab in hospitalized patients with severe pneumonia COVID-19: a cohort study","volume":"13","author":"Rossi","year":"2020","journal-title":"medRxiv"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/ITT.S202015","article-title":"Cytokine release syndrome: current perspectives","volume":"8","author":"Murthy","year":"2019","journal-title":"Immunotargets Ther"},{"key":"ref551","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237831","article-title":"Tocilizumab and steroid treatment in patients with COVID-19 pneumonia","volume":"15","author":"Mikulska","year":"2020","journal-title":"PLos One"},{"key":"ref1201","article-title":"https clinicaltrials gov ct show Accessed","volume":"11","year":"2021","journal-title":"Mar"},{"key":"ref1401","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41375-020-01087-z","article-title":"Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia","volume":"35","author":"D\u2019Alessio","year":"2021","journal-title":"Leukemia"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with Covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl J Med"},{"key":"ref1281","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1016\/S2665-9913(20)30277-0","article-title":"Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study","volume":"2","author":"Biran","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"ref1331","article-title":"Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection","author":"Moreno-Garc\u00eda","year":"2020","journal-title":"medRxiv"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/s41375-020-01018-y","article-title":"Compassionate use of JAK1\/2 inhibitor ruxolitinib for severe COVID-19: a retrospective observational study","volume":"35","author":"Vannucchi","year":"2021","journal-title":"Leukemia"},{"key":"ref1411","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41375-020-0891-0","article-title":"The Janus kinase 1\/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation","volume":"34","author":"La Ros\u00e9e","year":"2020","journal-title":"Leukemia"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40249-021-00857-w","article-title":"Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis","volume":"10","author":"Wei","year":"2021","journal-title":"Infect Dis Poverty"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with Covid-19 pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N Engl J Med"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"ref1221","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jamainternmed.2020.6252","article-title":"Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19","volume":"181","author":"Gupta","year":"2020","journal-title":"JAMA Intern Med"},{"key":"ref731","article-title":"https www fdanews com articles fda changes eua so olumiant can stand alone in treating covid v preview Accessed Jul","volume":"19","year":"2021"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"n84","DOI":"10.1136\/bmj.n84","article-title":"Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial","volume":"372","author":"Veiga","year":"2021","journal-title":"BMJ"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cmi.2020.10.036","article-title":"Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis","volume":"27","author":"Tleyjeh","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"ref1271","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/joim.13162","article-title":"Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study","volume":"289","author":"Eimer","year":"2021","journal-title":"J Intern Med"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/hon.2772","article-title":"Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide","volume":"38","author":"Sol\u00e1n","year":"2020","journal-title":"Hematol Oncol"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.tips.2020.06.007","article-title":"Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19","volume":"41","author":"Luo","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"ref111","article-title":"https www fda gov news events press announcements coronavirus covid update fda authorizes drug treatment covid Accessed","volume":"19","author":"Jun","year":"2021"},{"key":"ref521","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100459","article-title":"Early use of low dose tocilizumab in patients with COVID-19: a retrospective cohort study with a complete follow-up","author":"De Rossi","year":"2020","journal-title":"EClinicalMedicine"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe COVID-19 pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N Engl J Med"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"The Lancet"},{"key":"ref1531","article-title":"Disruption of the CCL5\/RANTES-CCR5 pathway restore immune homeostasis and reduces plasma viral load in critical COVID-19","author":"Patterson","year":"2020","journal-title":"medRxiv"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40249-021-00857-w","article-title":"Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis","volume":"10","author":"Wei","year":"2021","journal-title":"Infect Dis Poverty"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10875-020-00911-6","article-title":"Tocilizumab for severe worsening COVID-19 pneumonia: a propensity score analysis","volume":"41","author":"Roumier","year":"2021","journal-title":"J Clin Immunol"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41375-020-0891-0","article-title":"The Janus kinase 1\/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation","volume":"34","author":"La Ros\u00e9e","year":"2020","journal-title":"Leukemia"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fimmu.2020.00026","article-title":"Novel insights into immune systems of bats","volume":"11","author":"Banerjee","year":"2020","journal-title":"Front Immunol"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.chest.2020.09.275","article-title":"Comparative survival analysis of immunomodulatory therapy for COVID-19 \u2018cytokine storm\u2019","volume":"159","author":"Narain","year":"2020","journal-title":"Chest"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial","volume":"146","author":"Cao","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"ref121","article-title":"https www ema europa eu en news ema starts evaluating use roactemra hospitalised adults severe covid Accessed Aug","volume":"19","year":"2021"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/ITT.S202015","article-title":"Cytokine release syndrome: current perspectives","volume":"8","author":"Murthy","year":"2019","journal-title":"Immunotargets Ther"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-treatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"ref1161","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe COVID-19 pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N Engl J Med"},{"key":"ref1431","article-title":"https clinicaltrials gov ct show Accessed","author":"Jun","year":"2021"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-treatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the \u2018Cytokine Storm\u2019 in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"J Infect"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref691","first-page":"00331","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19 (COV-BARRIER): a randomized, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"S2213-2600","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ref1131","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial","volume":"181","author":"Salvarani","year":"2020","journal-title":"JAMA Intern Med"},{"key":"ref321","article-title":"Prognostic and predictive biomarkers in patients with COVID-19 treated with tocilizumab in a randomized controlled trial","author":"Tom","year":"2020","journal-title":"medRxiv"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/hon.2772","article-title":"Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide","volume":"38","author":"Sol\u00e1n","year":"2020","journal-title":"Hematol Oncol"},{"key":"ref1121","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41409-020-01060-5","article-title":"Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy","volume":"56","author":"Hong","year":"2021","journal-title":"Bone Marrow Transpl"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00134-021-06416-z","article-title":"Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials","volume":"47","author":"Snow","year":"2021","journal-title":"Intensive Care Med"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/joim.13162","article-title":"Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study","volume":"289","author":"Eimer","year":"2021","journal-title":"J Intern Med"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1186\/s12879-020-05701-4","article-title":"Effects of tocilizumab in COVID-19 patients: a cohort study","volume":"20","author":"Vu","year":"2020","journal-title":"BMC Infect Dis"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12879-021-05912-3","article-title":"Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India","volume":"21","author":"Gokhale","year":"2021","journal-title":"BMC Infect Dis"},{"key":"ref1191","doi-asserted-by":"crossref","first-page":"n84","DOI":"10.1136\/bmj.n84","article-title":"Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial","volume":"372","author":"Veiga","year":"2021","journal-title":"BMJ"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","article-title":"Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated","volume":"22","author":"Abboud","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"ref1291","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100459","article-title":"Early use of low dose tocilizumab in patients with COVID-19: a retrospective cohort study with a complete follow-up","author":"De Rossi","year":"2020","journal-title":"EClinicalMedicine"},{"key":"ref1311","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.chest.2020.09.275","article-title":"Comparative survival analysis of immunomodulatory therapy for COVID-19 \u2018cytokine storm\u2019","volume":"159","author":"Narain","year":"2020","journal-title":"Chest"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with COVID-19","volume":"384","author":"Gordon","year":"2021","journal-title":"N Engl J Med"},{"key":"ref491","article-title":"Off-label real wold experience using tocilizumab for patients hospitalized with COVID-19 disease in a regional community healt system: a case-control study","author":"Ramaswamy","year":"2020","journal-title":"medRxiv"},{"key":"ref1171","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with Covid-19 pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N Engl J Med"},{"key":"ref171","first-page":"145","article-title":"Laboratory parameters predicting mortality of adult in-patients with COVID-19 associated cytokine release syndrome treated with high-dose tocilizumab","volume":"68","author":"Lakatos","year":"2021","journal-title":"Acta Microbiol Immunol Hung"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy-assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"7546","DOI":"10.1200\/JCO.2020.38.15_suppl.7546","article-title":"Grade III-IV cytokine release syndrome is associated with inferior survival in patients undergoing haploidentical donor stem cell transplant","volume":"38","author":"Albanyan","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref1441","article-title":"https clinicaltrials gov ct show Accessed","volume":"15","year":"2021","journal-title":"Mar"},{"key":"ref1491","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jinf.2020.06.052","article-title":"Beneficial impact of baricitinib in COVID-19 moderate pneumonia; multicentre study","volume":"81","author":"Cantini","year":"2020","journal-title":"J Infect"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.16966","article-title":"Combined IL-6 and JAK\/STAT inhibitor therapy in COVID-19-related sHLH, potential game changer","volume":"190","author":"Portsmore","year":"2020","journal-title":"Br J Haematol"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ajcp\/aqaa124","article-title":"SARS-CoV-2 infection-associated hemophagocytic lymphohistiocytosis","volume":"154","author":"Prilutskiy","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/intimm\/dxab011","article-title":"IL-6: from arthritis to CAR-T-cell therapy and COVID-19","volume":"33","author":"Kishimoto","year":"2021","journal-title":"Int Immunol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1556\/650.2020.31901","article-title":"Successful administration of convalescent plasma in critically ill COVID-19 patients in Hungary: the first two cases","volume":"161","author":"Bobek","year":"2020","journal-title":"Orvosi Hetilap"}],"container-title":["Acta Microbiologica et Immunologica Hungarica"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/030\/68\/4\/article-p240.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/030\/68\/4\/article-p240.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/030\/68\/4\/article-p240.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T23:38:21Z","timestamp":1651534701000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/030\/68\/4\/article-p240.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":154,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1556\/030.2021.01620","relation":{},"ISSN":["1217-8950","1588-2640"],"issn-type":[{"value":"1217-8950","type":"print"},{"value":"1588-2640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]}}}